JP2024522855A5 - - Google Patents
Info
- Publication number
- JP2024522855A5 JP2024522855A5 JP2023579138A JP2023579138A JP2024522855A5 JP 2024522855 A5 JP2024522855 A5 JP 2024522855A5 JP 2023579138 A JP2023579138 A JP 2023579138A JP 2023579138 A JP2023579138 A JP 2023579138A JP 2024522855 A5 JP2024522855 A5 JP 2024522855A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- arginine
- polysorbate
- histidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214246P | 2021-06-23 | 2021-06-23 | |
| US202163214245P | 2021-06-23 | 2021-06-23 | |
| US63/214,246 | 2021-06-23 | ||
| US63/214,245 | 2021-06-23 | ||
| US202163214752P | 2021-06-24 | 2021-06-24 | |
| US63/214,752 | 2021-06-24 | ||
| US202163231909P | 2021-08-11 | 2021-08-11 | |
| US63/231,909 | 2021-08-11 | ||
| PCT/US2022/034747 WO2022271962A1 (en) | 2021-06-23 | 2022-06-23 | Formulations of factor viii chimeric proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522855A JP2024522855A (ja) | 2024-06-21 |
| JP2024522855A5 true JP2024522855A5 (enExample) | 2025-06-30 |
Family
ID=82656587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579138A Pending JP2024522855A (ja) | 2021-06-23 | 2022-06-23 | 第ｖｉｉｉ因子キメラタンパク質の製剤およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240287158A1 (enExample) |
| EP (1) | EP4358938A1 (enExample) |
| JP (1) | JP2024522855A (enExample) |
| KR (1) | KR20240024949A (enExample) |
| AU (1) | AU2022298798A1 (enExample) |
| BR (1) | BR112023026782A2 (enExample) |
| CA (1) | CA3220564A1 (enExample) |
| CO (1) | CO2023017358A2 (enExample) |
| IL (1) | IL309309A (enExample) |
| MX (1) | MX2023015238A (enExample) |
| TW (1) | TW202317178A (enExample) |
| WO (1) | WO2022271962A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172893A2 (en) * | 2022-03-08 | 2023-09-14 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124690C (en) * | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| MX339060B (es) * | 2008-11-07 | 2016-05-09 | Baxter Int | Formulaciones del factor viii. |
| CN104661674A (zh) | 2012-07-11 | 2015-05-27 | 阿穆尼克斯运营公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
| PL3793588T3 (pl) * | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| CN114007637A (zh) * | 2019-06-19 | 2022-02-01 | 比奥维拉迪维治疗股份有限公司 | 用于治疗血友病和低骨矿物质密度的重组因子viii-fc |
| US20220305089A1 (en) * | 2019-08-16 | 2022-09-29 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
-
2022
- 2022-06-23 US US18/572,006 patent/US20240287158A1/en active Pending
- 2022-06-23 TW TW111123492A patent/TW202317178A/zh unknown
- 2022-06-23 EP EP22744880.0A patent/EP4358938A1/en active Pending
- 2022-06-23 MX MX2023015238A patent/MX2023015238A/es unknown
- 2022-06-23 WO PCT/US2022/034747 patent/WO2022271962A1/en not_active Ceased
- 2022-06-23 JP JP2023579138A patent/JP2024522855A/ja active Pending
- 2022-06-23 IL IL309309A patent/IL309309A/en unknown
- 2022-06-23 BR BR112023026782A patent/BR112023026782A2/pt unknown
- 2022-06-23 KR KR1020247002191A patent/KR20240024949A/ko active Pending
- 2022-06-23 AU AU2022298798A patent/AU2022298798A1/en active Pending
- 2022-06-23 CA CA3220564A patent/CA3220564A1/en active Pending
-
2023
- 2023-12-14 CO CONC2023/0017358A patent/CO2023017358A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7168451B2 (ja) | 二重特異性抗体コンストラクトを含む医薬組成物 | |
| AU2003234743B2 (en) | Storage-stable, liquid fibrinogen formulation | |
| ES2371038T3 (es) | Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos. | |
| JP2024099628A5 (enExample) | ||
| Girma et al. | Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain | |
| JP3701028B2 (ja) | 高純度フォンビルブラント因子の入手方法 | |
| JP2020156520A5 (enExample) | ||
| US10357589B2 (en) | One component fibrin glue comprising a polymerization inhibitor | |
| JP2024099682A5 (enExample) | ||
| ES2409888T3 (es) | Purificación de un fibrinógeno | |
| ES2333374T3 (es) | Peptidos y derivados de peptidos, la produccion de los mismos asi como su uso para preparar una composicion farmaceutica terapeutica y/o preventivamente activa. | |
| JP6605593B2 (ja) | 第ｖｉｉｉ因子およびフォン・ヴィルブランド因子ペプチドを含む製剤 | |
| JP2022151814A5 (enExample) | ||
| JP2024522855A5 (enExample) | ||
| WO1990014103A1 (en) | Polypeptide-antibody conjugate for inhibiting cell adhesion | |
| AU2014237111B2 (en) | Recombinant factor VIII formulations | |
| KR101080622B1 (ko) | Ｖｉｉｉ:ｃ 인자-함유 폰 빌레브란트 인자의 농축물 및 이의 제조방법 | |
| CA3071930A1 (en) | Hemopexin formulations | |
| AU2010205403B2 (en) | New process for highly selective purification of two plasma proteins: von Willebrand factor (vWF) and Fibronectin (Fn) | |
| JP2022532445A (ja) | 新規な中間体製造による持続型薬物結合体の製造方法 | |
| WO2019219049A1 (zh) | 改进的fviii融合蛋白及其应用 | |
| US20050004040A1 (en) | Peptide having an affinity for gp120 | |
| JP2024538091A5 (enExample) | ||
| JPS6089433A (ja) | 制癌作用物質複合体の製造法 | |
| CN103130872A (zh) | 吸附剂、固相载体及精制方法 |